Medicine
Supprelin La 50 mg implant
Supprelin La 50 mg implant is a prescription medicine containing Histrelin for subcutaneous use, marketed by Endo, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
SUPPRELIN LA (NDC 67979-002-01) is supplied in a corrugated shipping carton…
Key facts
- Active ingredient (INN)
- Histrelin
- Brand
- Supprelin La
- Strength
- 50 mg
- Dosage form
- Implant
- Route
- Subcutaneous
- Packs
- 1 vial
- Marketing authorisation holder
- Endo
- Manufacturer
- Endo
- Origin register
- US FDA, United States
- Storage
- SUPPRELIN LA (NDC 67979-002-01) is supplied in a corrugated shipping carton that contains 2 inner cartons: a small one for the vial containing the SUPPRELIN LA implant, which is shipped with a cold pack inside a polystyrene cooler that must be refrigerated upon arrival, and a larger one comprising the Implantation Kit, which must not be refrigerated, for use during insertion or removal of…
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L02AE05 Histrelin
- HS code (indicative)
- 3004.39Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 31 May 2007
- Identifiers
- RxCUI 1294641, 1740437DailyMed set ID d8fb000e-3cc9-4803-b71d-2cc597661977NDC 67979-002Application NDA022058
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial, glass in 1 carton / 1 implant in 1 vial, glass | 67979-002-01 | Endo | 31 May 2007 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 24 December 1991 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Histrelin is a gonadotropin releasing hormone receptor agonist indicated for the treatment of children with central precocious puberty (CPP). It is available as implants for subcutaneous use. MedsAcross supplies Histrelin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about HistrelinFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- SUPPRELIN LA prescribing information (Endo) · U.S. National Library of Medicine, DailyMed
Need Supprelin La 50 mg implant for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.